Ribonucleic Acid Engineering of Dendritic Cells for Therapeutic Vaccination: Ready 'N Able to Improve Clinical Outcome?

Overview

Journal Cancers (Basel)

Publisher MDPI

Specialty Oncology

Date 2020 Feb 5

PMID 32012714

Citations 2

Authors

Yannick Willemen

Maarten Versteven

Marc Peeters

Zwi N Berneman

Evelien L J Smits

Affiliations

Soon will be listed here.

Abstract

Targeting and exploiting the immune system has become a valid alternative to conventional options for treating cancer and infectious disease. Dendritic cells (DCs) take a central place given their role as key orchestrators of immunity. Therapeutic vaccination with autologous DCs aims to stimulate the patient's own immune system to specifically target his/her disease and has proven to be an effective form of immunotherapy with very little toxicity. A great amount of research in this field has concentrated on engineering these DCs through ribonucleic acid (RNA) to improve vaccine efficacy and thereby the historically low response rates. We reviewed in depth the 52 clinical trials that have been published on RNA-engineered DC vaccination, spanning from 2001 to date and reporting on 696 different vaccinated patients. While ambiguity prevents reliable quantification of effects, these trials do provide evidence that RNA-modified DC vaccination can induce objective clinical responses and survival benefit in cancer patients through stimulation of anti-cancer immunity, without significant toxicity. Succinct background knowledge of RNA engineering strategies and concise conclusions from available clinical and recent preclinical evidence will help guide future research in the larger domain of DC immunotherapy.

Citing Articles

A review of the clinical experience with CMN-001, a tumor RNA loaded dendritic cell immunotherapy for the treatment of metastatic renal cell carcinoma.

DeBenedette M, Gamble A, Norris M, Horvatinovich J, Nicolette C Hum Vaccin Immunother. 2023; 19(2):2220629.

PMID: 37387210 PMC: 10332239. DOI: 10.1080/21645515.2023.2220629.

Insights Into Dendritic Cells in Cancer Immunotherapy: From Bench to Clinical Applications.

Salah A, Wang H, Li Y, Ji M, Ou W, Qi N Front Cell Dev Biol. 2021; 9:686544.

PMID: 34262904 PMC: 8273339. DOI: 10.3389/fcell.2021.686544.

References

Bassani-Sternberg M, Digklia A, Huber F, Wagner D, Sempoux C, Stevenson B . A Phase Ib Study of the Combination of Personalized Autologous Dendritic Cell Vaccine, Aspirin, and Standard of Care Adjuvant Chemotherapy Followed by Nivolumab for Resected Pancreatic Adenocarcinoma-A Proof of Antigen Discovery Feasibility in Three.... Front Immunol. 2019; 10:1832. PMC: 6694698. DOI: 10.3389/fimmu.2019.01832. View

Kyte J, Kvalheim G, Lislerud K, Straten P, Dueland S, Aamdal S . T cell responses in melanoma patients after vaccination with tumor-mRNA transfected dendritic cells. Cancer Immunol Immunother. 2006; 56(5):659-75. PMC: 11030282. DOI: 10.1007/s00262-006-0222-y. View

De Keersmaecker B, Heirman C, Corthals J, Empsen C, van Grunsven L, Allard S . The combination of 4-1BBL and CD40L strongly enhances the capacity of dendritic cells to stimulate HIV-specific T cell responses. J Leukoc Biol. 2011; 89(6):989-99. DOI: 10.1189/jlb.0810466. View

Boczkowski D, Nair S, Snyder D, Gilboa E . Dendritic cells pulsed with RNA are potent antigen-presenting cells in vitro and in vivo. J Exp Med. 1996; 184(2):465-72. PMC: 2192710. DOI: 10.1084/jem.184.2.465. View

Mastelic-Gavillet B, Balint K, Boudousquie C, Gannon P, Kandalaft L . Personalized Dendritic Cell Vaccines-Recent Breakthroughs and Encouraging Clinical Results. Front Immunol. 2019; 10:766. PMC: 6470191. DOI: 10.3389/fimmu.2019.00766. View

Guo C, Yi H, Yu X, Zuo D, Qian J, Yang G . In situ vaccination with CD204 gene-silenced dendritic cell, not unmodified dendritic cell, enhances radiation therapy of prostate cancer. Mol Cancer Ther. 2012; 11(11):2331-41. PMC: 3496075. DOI: 10.1158/1535-7163.MCT-12-0164. View

De Temmerman M, Dewitte H, Vandenbroucke R, Lucas B, Libert C, Demeester J . mRNA-Lipoplex loaded microbubble contrast agents for ultrasound-assisted transfection of dendritic cells. Biomaterials. 2011; 32(34):9128-35. DOI: 10.1016/j.biomaterials.2011.08.024. View

Schreiber R, Old L, Smyth M . Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science. 2011; 331(6024):1565-70. DOI: 10.1126/science.1203486. View

Nair S, Boczkowski D, Moeller B, Dewhirst M, Vieweg J, Gilboa E . Synergy between tumor immunotherapy and antiangiogenic therapy. Blood. 2003; 102(3):964-71. DOI: 10.1182/blood-2002-12-3738. View

10.

Amin A, Dudek A, Logan T, Lance R, Holzbeierlein J, Knox J . Survival with AGS-003, an autologous dendritic cell-based immunotherapy, in combination with sunitinib in unfavorable risk patients with advanced renal cell carcinoma (RCC): Phase 2 study results. J Immunother Cancer. 2015; 3:14. PMC: 4404644. DOI: 10.1186/s40425-015-0055-3. View

11.

Dorrie J, Schaft N, Muller I, Wellner V, Schunder T, Hanig J . Introduction of functional chimeric E/L-selectin by RNA electroporation to target dendritic cells from blood to lymph nodes. Cancer Immunol Immunother. 2007; 57(4):467-77. PMC: 11041385. DOI: 10.1007/s00262-007-0385-1. View

12.

Chen J, Guo X, Li H, Wang D, Shao X . Comparison of cytotoxic T lymphocyte responses against pancreatic cancer induced by dendritic cells transfected with total tumor RNA and fusion hybrided with tumor cell. Exp Biol Med (Maywood). 2015; 240(10):1310-8. PMC: 4935259. DOI: 10.1177/1535370215571884. View

13.

Sever A, Mills P, Jones S, Cox K, Weeks J, Fish D . Preoperative sentinel node identification with ultrasound using microbubbles in patients with breast cancer. AJR Am J Roentgenol. 2011; 196(2):251-6. DOI: 10.2214/AJR.10.4865. View

14.

Reap E, Suryadevara C, Batich K, Sanchez-Perez L, Archer G, Schmittling R . Dendritic Cells Enhance Polyfunctionality of Adoptively Transferred T Cells That Target Cytomegalovirus in Glioblastoma. Cancer Res. 2017; 78(1):256-264. PMC: 5754236. DOI: 10.1158/0008-5472.CAN-17-0469. View

15.

Anguille S, Van de Velde A, Smits E, Van Tendeloo V, Juliusson G, Cools N . Dendritic cell vaccination as postremission treatment to prevent or delay relapse in acute myeloid leukemia. Blood. 2017; 130(15):1713-1721. PMC: 5649080. DOI: 10.1182/blood-2017-04-780155. View

16.

Tanyi J, Bobisse S, Ophir E, Tuyaerts S, Roberti A, Genolet R . Personalized cancer vaccine effectively mobilizes antitumor T cell immunity in ovarian cancer. Sci Transl Med. 2018; 10(436). DOI: 10.1126/scitranslmed.aao5931. View

17.

Gottschalk S, Yu F, Ji M, Kakarla S, Song X . A vaccine that co-targets tumor cells and cancer associated fibroblasts results in enhanced antitumor activity by inducing antigen spreading. PLoS One. 2013; 8(12):e82658. PMC: 3861387. DOI: 10.1371/journal.pone.0082658. View

18.

Van Tendeloo V, Ponsaerts P, Berneman Z . mRNA-based gene transfer as a tool for gene and cell therapy. Curr Opin Mol Ther. 2007; 9(5):423-31. View

19.

Nair S, Boczkowski D, Morse M, Cumming R, Lyerly H, Gilboa E . Induction of primary carcinoembryonic antigen (CEA)-specific cytotoxic T lymphocytes in vitro using human dendritic cells transfected with RNA. Nat Biotechnol. 1998; 16(4):364-9. DOI: 10.1038/nbt0498-364. View

20.

Zhang H, Zhang L, Liu W, Cheng J, Si X, Ren J . Comparative analysis of DC fused with tumor cells or transfected with tumor total RNA as potential cancer vaccines against hepatocellular carcinoma. Cytotherapy. 2006; 8(6):580-8. DOI: 10.1080/14653240600991353. View